Analyst Ratings For NeuroDerm (NASDAQ:NDRM)
Today, NeuroDerm (NASDAQ:NDRM) stock was downgraded by Roth Capital from Buy to Neutral with a price target of $39.00.
There are 3 hold ratings, 5 buy ratings on the stock.
The current consensus rating on NeuroDerm (NASDAQ:NDRM) is Buy (Score: 2.63) with a consensus target price of $45.86 per share, a potential 18.65% upside.
Some recent analyst ratings include
- 8/2/2017-Roth Capital was Downgraded by analysts at Roth Capital from a “Buy ” rating to a ” Neutral” rating. They now have a $39.00 price target on the stock.
- 7/24/2017-Raymond James Financial, Inc. was Downgraded by analysts at Raymond James Financial, Inc. from a “Outperform ” rating to a ” Market Perform” rating. They now have a $39.00 price target on the stock.
- 7/21/2017-Deutsche Bank AG initiated coverage with a Buy rating.
- 6/14/2017-CIBC Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 6/14/2017-Oppenheimer Holdings, Inc. Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
- 4/24/2017-Jefferies Group LLC Reiterated Rating of Buy.
- 3/7/2017-Citigroup Inc. was Downgraded by analysts at Citigroup Inc. from a “Outperform ” rating to a ” Market Perform” rating.
Recent Trading Activity for NeuroDerm (NASDAQ:NDRM)
Shares of NeuroDerm closed the previous trading session at 38.65 0.00 0.00% with 393,674 shares trading hands.
